Haisco licenses inflammatory disease drug to Sentivera; ViiV's HIV drug cleared for newborns
Haisco Pharmaceutical has granted US startup Sentivera ex-China rights to an unnamed inflammatory disease drug. Separately, ViiV Healthcare's HIV treatment has received approval for use in newborns. The two developments mark progress in different therapeutic areas.
The two announcements highlight distinct fronts in pharmaceutical progress. Haisco’s licensing deal with Sentivera reflects a growing pattern of Chinese drugmakers partnering with Western biotechs to advance experimental therapies into new markets, particularly for chronic inflammatory conditions. Meanwhile, ViiV’s regulatory clearance for its HIV drug in newborns addresses a critical gap in pediatric treatment, where dosing and safety data have historically lagged behind adult approvals. Together, these moves underscore how drug development continues to diversify across geographies and patient populations, even as the underlying science remains complex and costly.
These developments could broaden access to treatments for patients who currently have limited options—newborns with HIV and adults with inflammatory diseases. If the licensed drug proves effective, it may offer relief to millions living with chronic conditions, while the newborn approval could reduce transmission-related complications early in life. However, real-world impact depends on pricing, manufacturing, and eventual clinical outcomes. Patients and healthcare systems may benefit from increased competition and innovation, but timelines for availability remain uncertain.